“The Leber’s Hereditary Optic Neuropathy Market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Leber’s Hereditary Optic Neuropathy pipeline products will significantly revolutionize the A Leber’s Hereditary Optic Neuropathy market dynamics”
The Leber’s Hereditary Optic Neuropathy market report provides current treatment practices, Leber’s Hereditary Optic Neuropathy emerging drugs, market share of individual therapies, and current and forecasted 7MM Leber’s Hereditary Optic Neuropathy market size from 2019 to 2032. The report also covers current Leber’s Hereditary Optic Neuropathy treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.
Key Takeaways from the Leber’s Hereditary Optic Neuropathy Market Research Report
- The increased number of Leber’s Hereditary Optic Neuropathy (LHON) cases along with the emerging treatment, is likely to contribute directly to the market growth during the forecast period (2023–2032).
- The leading companies working in the Leber’s Hereditary Optic Neuropathy Market include GenSight Biologics, Neurophth Therapeutics, Mitotech, Stealth BioTherapeutics, Fortify Therapeutics, Neuroptika, and others.
- Promising Leber’s Hereditary Optic Neuropathy Pipeline Therapies in the various stages of development GS010, Idebenone, QPI-1007 at various doses, Cysteamine Bitartrate, and others.
- April 2023: Santhera Pharmaceuticals announced a study of Phase 4 Clinical Trials for Idebenone. LEROS is an open-label interventional Phase IV study, designed to further assess the efficacy and safety of Raxone® in the long-term treatment of LHON patients.
- August 2023: GenSight Biologics announced a study of Phase 3 clinical trials for GS010. The goal of this clinical trial is to assess the safety and efficacy of GS010, a gene therapy, in improving the retina functional & structural outcomes in subjects with LHON due to the G11778A ND4 mitochondrial mutation when vision loss duration is present up to one year.
Discover more about therapies set to grab major Leber’s Hereditary Optic Neuropathy Market Share @ Leber’s Hereditary Optic Neuropathy Market Size
Leber’s Hereditary Optic Neuropathy Overview
Leber’s hereditary optic neuropathy (LHON) is a distinct type of “inherited optic atrophies” or “hereditary optic neuropathies.” It refers to an optic nerve dysfunction due to point mutations in the mitochondrial DNA and is transmitted in non-mendelian pattern.
Leber’s Hereditary Optic Neuropathy Epidemiology Segmentation in the 7MM
- Total Leber’s Hereditary Optic Neuropathy Prevalent Cases
- Leber’s Hereditary Optic Neuropathy Gender-specific Diagnosed Prevalent Cases
- Leber’s Hereditary Optic Neuropathy Diagnosed Prevalent Cases
- Leber’s Hereditary Optic Neuropathy Mutation-specific Diagnosed Prevalent Cases
Download the report to understand which factors are driving Leber’s Hereditary Optic Neuropathy Epidemiology Trends @ Leber’s Hereditary Optic Neuropathy Epidemiological Insights
Leber’s Hereditary Optic Neuropathy Market Size
The Leber’s Hereditary Optic Neuropathy market size is expected to undergo significant changes in the upcoming years due to the anticipated launch of emerging therapies such as GS010 – LUMEVOQ, NFS-01 (NR082, rAAV-ND4) and NFS-02 (rAAV-ND1) and several others, which are in development to treat Leber’s Hereditary Optic Neuropathy.
Leber’s Hereditary Optic Neuropathy Treatment Market
The treatment of mitochondrial disorders is still in its infancy, even though there is promising research underway. Idebenone (Raxone), which is the only authorized therapy for LHON has only limited benefits. Leber hereditary optic neuropathy remains a seriously debilitating disease with a continued unmet medical need for efficacious therapies.
To know more about Leber’s Hereditary Optic Neuropathy Treatment options, visit @ Leber’s Hereditary Optic Neuropathy Drugs
Leber’s Hereditary Optic Neuropathy Market Dynamics
The Leber’s Hereditary Optic Neuropathy market dynamics are anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2019-2032 such as GS010 (GenSight) and NFS-01 (NR082, rAAV-ND4) (Nuerophth). The overall Leber’s Hereditary Optic Neuropathy (LHON) pipeline is expected to undergo a paradigm shift in the coming years owing to large-scale changes in the market composition, a dynamic process that has already started taking shape since 2019. Launching various multiple-stage pipeline products will significantly revolutionize the Leber’s Hereditary Optic Neuropathy market dynamics.
Leber’s Hereditary Optic Neuropathy Market Forecast
According to DelveInsight’s’ estimates, the Leber’s Hereditary Optic Neuropathy market forecast in 7MM is expected to show positive growth, during the forecast period (2023–2032), mainly attributed to the anticipated launch of emerging therapy and the increasing cases of Leber’s Hereditary Optic Neuropathy.
Learn more about the Leber’s Hereditary Optic Neuropathy Pipeline Therapies in clinical trials @ Leber’s Hereditary Optic Neuropathy Market Landscape
Scope of the Leber’s Hereditary Optic Neuropathy Market Research Report
- Coverage- 7MM
- Study Period- 2019-2032
- Forecast Period- 2023-2032
- Leber’s Hereditary Optic Neuropathy Companies- GenSight Biologics (NYSE: SIGHT.PA), Neurophth Therapeutics, Mitotech, Stealth BioTherapeutics (NYSE: MITO), Fortify Therapeutics, Neuroptika, and others.
- Leber’s Hereditary Optic Neuropathy Pipeline Therapies- GS010, Idebenone, QPI-1007 at various doses, Cysteamine Bitartrate, and others.
- Leber’s Hereditary Optic Neuropathy Market Dynamics: Leber’s Hereditary Optic Neuropathy Market Drivers and Barriers
- Leber’s Hereditary Optic Neuropathy Market Access and Reimbursement, Unmet Needs, and Future Perspectives
Discover more about Leber’s Hereditary Optic Neuropathy Drugs in development @ Leber’s Hereditary Optic Neuropathy Ongoing Clinical Trials Analysis
Table of Content
- Key Insights
- Executive Summary of Leber’s Hereditary Optic Neuropathy (LHON)
- Competitive Intelligence Analysis for Leber’s Hereditary Optic Neuropathy (LHON)
- Leber’s Hereditary Optic Neuropathy Market Overview at a Glance
- Leber’s Hereditary Optic Neuropathy Market Disease Background and Overview
- Leber’s hereditary optic neuropathy Patient Journey
- Leber’s Hereditary Optic Neuropathy Epidemiology and Patient Population
- Leber’s hereditary optic neuropathy Treatment Algorithm, Current Treatment, and Medical Practices
- Leber’s Hereditary Optic Neuropathy Unmet Needs
- Key Endpoints of Leber’s Hereditary Optic Neuropathy Treatment
- Leber’s Hereditary Optic Neuropathy Marketed Products
- Leber’s Hereditary Optic Neuropathy Emerging Therapies
- Leber’s Hereditary Optic Neuropathy: Seven Major Market Analysis
- Attribute analysis
- 7MM: Leber’s hereditary optic neuropathy Market Outlook
- Access and Reimbursement Overview of Leber’s Hereditary Optic Neuropathy (LHON)
- KOL Views
- Leber’s hereditary optic neuropathy Market Drivers
- Leber’s hereditary optic neuropathy Market Barriers
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
List of Top Selling Market Research Reports in 2023
Allergic Asthma due to Dermatophagoides Farinae Market | Angiofibroma Market | Atrial Flutter Market | Chronic Traumatic Encephalopathy Market | Congenital ichthyosis Market | Coronary Microvascular Dysfunction Market | Digestive System Fistula Market | Facial Lines Market | Japan Healthcare Outlook Market | Moderate Psoriasis Market | Myopia Treatment Devices Market | Palmar Fibromatosis Market | Palmoplantar Pustulosis Market | Paranasal Sinus Cancer Market | Partial Paralysis Market | Primary Mediastinal Large B-Cell Lymphoma Market | Proteus Syndrome Market | Ptosis Market | Renal Tubular Acidosis Market | Small Lymphocytic Lymphoma Market | Systemic Mastocytosis Market | Thymidine Kinase 2 Deficiency Market | Transverse Myelitis Market | UK Healthcare Outlook Report | Urethral Stricture Treatment Devices Market | Varicella Zoster (HHV-3) Infections Market | Bacterial Pneumonia Market | Blastomycosis Market | Bowel Obstruction Market | Coccidioidomycosis Market | Erosive Hand Osteoarthritis Market | Familial Lipoprotein Lipase Deficiency Market | Intracranial Hemorrhage Devices Market | Japan Healthcare Outlook | Lambert-Eaton Myasthenic Syndrome Market | Mild To Moderate Plaque Psoriasis Market | Neurofibromatosis Type 2 Market | Oral Electrolyte Solutions Market | Parainfluenza Virus Infection Market | Persistent Epithelial Defect Market | Plaque Modification Devices Market | Postherpetic Neuralgia Market | Primary Ciliary Dyskinesia Market | Propionic Acidemia Market | Radiation-induced Esophagitis Market | Sly Syndrome Market | Tourette Syndrome Market | Wiskott-aldrich Syndrome Market | Familial Lipoprotein Lipase Deficiency Pipeline | Farber’s Disease Market | Geographic Atrophy Market | Heart Failure Market | Human Papillomavirus-positive Oropharyngeal Cancer Market | Inflammatory Pain Market | Intraocular Lymphoma Market | Meibomian Gland Dysfunction Market | Neurodermatitis Market | Persistent Depressive Disorder Market | Secondary Progressive Multiple Sclerosis Market | Sick Sinus Syndrome Market | Soft Tissue Defect Market| Supraventricular Tachycardia Market | Tay-Sachs Disease Market | Uveal Neoplasms Market | Angio Suites Market | Canaloplasty Market | Coronary Microvascular Dysfunction Market | Exosomes Pipeline | Hepatic Cirrhosis Market | House Dust Mite Allergy Market | Hypertriglyceridemia Market | Langerhans Cell Histiocytosis Market | Non-Muscle Invasive Bladder Cancer Market | Pancreatic Endocrine Tumor Market | Peripheral Nerve Injuries Market | Shigella Infections Market | Spinocerebellar Ataxias Market | Syphilis Market | Urothelial Carcinoma Market | Uveal Melanoma Market | Von Hippel-Lindau Disease Market | Acute Myeloid Leukemia Market | Adult T-Cell Leukemia-Lymphoma Market | Advanced Liver Cancer Market | Carcinoid Syndrome Market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers and acquisitions.